Straits Times Index
3,258.90 +1.72 (+0.05%) Nikkei
28,041.48 +258.55 (+0.93%) Hang Seng
20,400.11 +90.98 (+0.45%) FTSE 100
7,639.33 +18.90 (+0.25%) Bitcoin USD
27,917.51 -704.45 (-2.46%) CMC Crypto 200
610.64 -8.60 (-1.39%)
Repare Therapeutics Inc. (RPTX)
Pre-market:
| Previous close | 9.74 |
| Open | 9.74 |
| Bid | 9.10 x 1100 |
| Ask | 11.36 x 1000 |
| Day's range | 9.30 - 9.76 |
| 52-week range | 8.06 - 18.68 |
| Volume | |
| Avg. volume | 133,380 |
| Market cap | 415.555M |
| Beta (5Y monthly) | 0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.67 |
| Earnings date | 03 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.00 |
- Business Wire
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306
CAMBRIDGE, Mass. & MONTREAL, March 14, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib (RP-3500/RG6526, partnered with Roche) in combination with three poly (ADP-ribose) polymerase inhibitors (PARPi) has been selected for the clinical plenary session at the 2023 AACR Annual Meeting, held April 14-19, 2023, in Orlando, Florida. An AACR assigned
- Zacks
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
CAMBRIDGE, Mass. & MONTREAL, February 28, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2022.
